[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100629985":3},{"organization":4,"armGroups":7,"interventions":21,"overallOfficials":27,"centralContacts":36,"locations":44,"responsibleParty":87,"collaborators":27,"id":90,"slug":91,"hasResults":92,"nctId":93,"briefTitle":94,"officialTitle":95,"acronym":27,"eligibilityCriteria":96,"healthyVolunteers":92,"sex":97,"minAge":98,"maxAge":27,"enrollmentInfo":99,"targetDuration":27,"studyType":102,"phases":103,"briefSummary":105,"conditions":106,"keywords":111,"overallStatus":47,"whyStopped":27,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":123},{"fullName":5,"class":6},"Sun Yat-sen University","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"The FSRT-beva group","EXPERIMENTAL","The FSRT-bevacizumab group receives FSRT plus bevacizumab. FSRT targets visible intracranial lesions, with a total dose of 30 Gy administered once daily for 5 fractions (6 Gy per fraction). Bevacizumab is initiated one week before the start of FSRT and administered every 3 weeks for a total of 4 cycles, via intravenous injection at a dose of 7.5 mg\u002Fkg.",[13,14],"Radiation: FSRT","Drug: Bevacizumab",{"label":16,"type":17,"description":18,"interventionNames":19},"The HA-WBRT-SIB group","ACTIVE_COMPARATOR","The HA-WBRT-SIB group receives whole-brain radiotherapy with hippocampal avoidance and a simultaneous integrated boost (SIB) to visible intracranial lesions. A total dose of 25 Gy is delivered to the whole brain, while visible lesions are simultaneously boosted to 40 Gy. Treatment is administered once daily for a total of 10 fractions.",[20],"Radiation: HA-WBRT-SIB",[22,28,31],{"type":23,"name":24,"description":25,"armGroupLabels":26,"otherNames":27},"RADIATION","FSRT","The FSRT-bevacizumab group receives FSRT plus bevacizumab. FSRT targets visible intracranial lesions, with a total dose of 30 Gy administered once daily for 5 fractions (6 Gy per fraction).",[9],null,{"type":23,"name":29,"description":18,"armGroupLabels":30,"otherNames":27},"HA-WBRT-SIB",[16],{"type":32,"name":33,"description":34,"armGroupLabels":35,"otherNames":27},"DRUG","Bevacizumab","Bevacizumab is initiated one week before the start of FSRT and administered every 3 weeks for a total of 4 cycles, via intravenous injection at a dose of 7.5 mg\u002Fkg.",[9],[37,42],{"name":38,"role":39,"phone":40,"phoneExt":27,"email":41},"Hui Liu","CONTACT","02087343031","liuhuisysucc@126.com",{"name":43,"role":39,"phone":40,"phoneExt":27,"email":27},"Bo Qiu",[45,63,76],{"facility":46,"status":47,"city":48,"state":49,"zip":50,"country":51,"countryCode":52,"cosmosGeoPoint":53,"geoPoint":58,"contacts":59},"The First Affiliated Hospital of Chongqing Medical University","RECRUITING","Chongqing","Chongqing Municipality","400016","China","CN",{"type":54,"coordinates":55},"Point",[56,57],106.55771,29.56026,{"lat":57,"lon":56},[60],{"name":61,"role":39,"phone":27,"phoneExt":27,"email":62},"Rui Zhou, Doctor","tumorrui@163.com",{"facility":64,"status":47,"city":65,"state":66,"zip":67,"country":51,"countryCode":52,"cosmosGeoPoint":68,"geoPoint":72,"contacts":73},"Sun yat-sen University Cancer Center","Guangzhou","Guangdong","510060",{"type":54,"coordinates":69},[70,71],113.25,23.11667,{"lat":71,"lon":70},[74],{"name":38,"role":39,"phone":75,"phoneExt":27,"email":41},"86-020-87343031",{"facility":77,"status":47,"city":65,"state":66,"zip":78,"country":51,"countryCode":52,"cosmosGeoPoint":79,"geoPoint":81,"contacts":82},"The First Affiliated Hospital of Guangzhou University of Chinese Medicine","510405",{"type":54,"coordinates":80},[70,71],{"lat":71,"lon":70},[83],{"name":84,"role":39,"phone":85,"phoneExt":27,"email":86},"Linzhu Zhai, Doctor","86-020-36492585","linzhuzhai@163.com",{"type":88,"investigatorFullName":38,"investigatorTitle":89,"investigatorAffiliation":5,"oldNameTitle":27,"oldOrganization":27},"PRINCIPAL_INVESTIGATOR","Professer","100629985","phase-3-bevacizumab-plus-fsrt-versus-hippocampus-avoidant-wbrt-in-lung-adenocarcinoma-with-extensive-brain-metastases-100629985",false,"NCT07481786","Bevacizumab Plus FSRT Versus Hippocampus-Avoidant WBRT in Lung Adenocarcinoma With Extensive Brain Metastases","Application of Bevacizumab Combined With Fractionated Stereotactic Radiotherapy (FSRT-Bev) Versus Hippocampus-Avoidant Whole-Brain Radiotherapy With Simultaneous Integrated Boost (HA-WBRT-SIB) in Patients With Extensive Brain Metastases From Lung Adenocarcinoma: A Phase III Randomized Controlled Trial Evaluating Intracranial Control Efficacy and Neurocognitive Function","Inclusion Criteria:\n\n* Age ≥18 years\n* Pathologically confirmed non-squamous non-small cell lung cancer (adenocarcinoma)\n* Extensive brain metastases meeting any of the following:\n\n1-2 metastases with at least one ≥3 cm in diameter; or 3-10 metastases with at least one ≥2 cm; or 11-20 metastases\n\n* Stable extracranial disease\n* ECOG performance status 0-2\n* Adequate bone marrow, hepatic, and renal function\n* Written informed consent\n\nExclusion Criteria:\n\n* Contraindications to bevacizumab (uncontrolled hypertension, history of bleeding\u002Fthromboembolism, recent surgery, etc.)\n* Leptomeningeal metastasis\n* Prior brain radiotherapy or surgical resection of brain metastases\n* Significant mass effect requiring urgent neurosurgical intervention\n* Severe cardiovascular, vascular, or gastrointestinal disease within 6 months\n* Proteinuria ≥3+ or 24-hour urine protein \\>1 g\n* Other active malignancies (except curable non-melanoma skin cancer or cervical carcinoma in situ)\n* Inability to comply with neurocognitive testing\n* Pregnancy or breastfeeding","ALL","18 Years",{"count":100,"type":101},220,"ESTIMATED","INTERVENTIONAL",[104],"PHASE3","This is a phase 3, randomized, controlled clinical trial comparing two brain-directed treatment strategies for adult patients with extensive brain metastases from lung adenocarcinoma. The trial compares fractionated stereotactic radiotherapy combined with bevacizumab (FSRT-Bev) versus hippocampus-avoidant whole-brain radiotherapy with simultaneous integrated boost (HA-WBRT-SIB). The main objectives are to evaluate intracranial tumor control and preservation of neurocognitive function .\n\nPatients will be randomly assigned in a 1:1 ratio to receive either FSRT plus bevacizumab or HA-WBRT-SIB. In the experimental group, FSRT is delivered to visible brain tumors over 5 daily treatments (total 30 Gy, 6 Gy per fraction). Bevacizumab is given intravenously every 3 weeks for 4 cycles. In the control group, patients receive hippocampus-avoidant whole-brain radiation (25 Gy) with a simultaneous dose boost to metastatic lesions (40 Gy total) over 10 daily treatments.",[107,108,109,33,110],"Lung Adenocarcinoma","Brain Metastases","Radiotherapy, Intensity-Modulated","Whole-Brain Radiotherapy",[107,108,112,33,113],"fractionated stereotactic radiotherapy (FSRT)","Whole-brain radiotherapy with simultaneous integrated boost (HA-WBRT-SIB)","2026-04-03",{"date":116,"type":117},"2026-04-06","ACTUAL",{"date":119,"type":117},"2026-03-20",{"date":121,"type":101},"2029-09-15",{"name":5,"class":6},3]